News Lilly weakens on oral weight-loss drug data Shares in Eli Lilly have come under pressure after reporting the results of a phase 3 trial of oral weight-loss candidate orforglipron.
News Bayer's job cull nears 12,000, with more to come The reduction in Bayer's workforce under turnaround chief executive Bill Anderson has reached around 12,000 – and isn't yet completed.
News Novo Nordisk weakens again on interim results readout Novo Nordisk's already depressed share price has fallen again this morning, despite reporting an 18% increase in sales in the first half of this year.
News GSK suffers a setback with its TIM-3 programme GSK has become the latest drugmaker to run into difficulties in developing a drug targeting the immune checkpoint receptor TIM-3.
News Novo Nordisk slumps as it cuts sales forecast, names new CEO Novo Nordisk has a new CEO, facing an uphill battle to restore the fortunes of its US business as diabetes and obesity drugs come under pressure.
News MSD trims outlook as it aims to shave $3bn off costs MSD is embarking on a $3bn cost-reduction drive to prepare for the loss of patent protection for cancer blockbuster Keytruda.
R&D The long-delayed promise of the microbiome, with Sam Possemi... Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
